Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement
News Jun 26, 2009
Cenix BioScience GmbH has announced that they have signed a new multi-project research agreement with AstraZeneca, thereby expanding their relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.
The new agreement calls for Cenix to complete at least three major projects applying same platform for RNAi-based research that has now been utilized by major industry clients and partners in the EU and North America.
The work will integrate multi-pass genome-scale screens for the discovery of novel therapeutic target candidates with detailed validation analyses, all using a number of primary human cell types.
Cenix will adapt assays initially developed by AstraZeneca scientists, combining several complementary technology platforms including automated microscopy with Cellenger-based image analysis, to optimize their implementation as high throughput RNAi studies in 384-well and/or 1,536-well formats.
“We particularly welcome the approach chosen by AstraZeneca here, of tightly integrating the discovery screens with subsequent validation studies, a strategy that we have been strongly advocating for some years,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We also greatly appreciate and value the continuing trust that is manifested by this expanded relationship, whose full potential we look forward to realizing together in the months and years to come.”
Financial terms were not disclosed.
Early Life Experiences Alter DNA Structure in the Adult BrainNews
Scientists report in the journal Science that the type of mothering a female mouse provides her pups actually changes their DNA.READ MORE
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE